Skip to Content

RINVOQ 30 mg prolonged-release tablets

Licence status
Authorised: 16/12/2019
Active substances
Upadacitinib Hemihydrate
Dosage Form
Prolonged-release tablet
Licence number
EU/1/19/1404/006-009
Licence holder
AbbVie Deutschland GmbH & Co. KG

Licence information

ATC code
L04AA Selective immunosuppressants, L04AA44 upadacitinib
Legal supply status
Product subject to prescription which may not be renewed (A)
Place of sale
Supply through pharmacies only
Conditions of Licence
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing availability
Unknown
Advertising conditions
Advertising to healthcare professionals only
Licence issued
16/12/2019